Physician profile
Samuel Willis
NPI 1770586588
$1,943.37
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $566 · 2021: $367 · 2022: $33.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.66 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.02 | 2019-2021 | |
| Janssen Biotech, INC. | $285.65 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.90 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $73.85 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $66.14 | 2019-2020 | |
| Gilead Sciences, INC. | $54.43 | 2020-2021 | |
| Ucb, INC. | $43.01 | 2019-2020 | |
| Braintree Laboratories, INC. | $38.48 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $33.24 | 2019-2021 | |
| Pfizer INC. | $29.80 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $24.95 | 2019 | |
| Boston Scientific Corporation | $18.50 | 2020 | |
| Alfasigma USA, INC. | $15.32 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.93 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $13.65 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.